Compounds > deferasirox
Page last updated: 2024-09-05

deferasirox and Stomach Neoplasms

deferasirox has been researched along with Stomach Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jeong, YA; Joung, SY; Kang, S; Kim, BR; Kim, JL; Lee, DH; Lee, SI; Lee, SY; Min, BW; Na, YJ; Oh, SC1
Choi, JH; Kim, JS; Lee, YY; Park, BB; Uhm, J; Won, YW1

Other Studies

2 other study(ies) available for deferasirox and Stomach Neoplasms

ArticleYear
Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:7

    Topics: Apoptosis; Benzoates; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deferasirox; Deferoxamine; Endoplasmic Reticulum Stress; Humans; Iron Chelating Agents; JNK Mitogen-Activated Protein Kinases; Microscopy, Confocal; Neoplasm Staging; Prognosis; Reactive Oxygen Species; Siderophores; Signal Transduction; Stomach Neoplasms; Triazoles; Tumor Cells, Cultured

2016
The potential of deferasirox as a novel therapeutic modality in gastric cancer.
    World journal of surgical oncology, 2016, Mar-10, Volume: 14

    Topics: Antineoplastic Agents; Apoptosis; Benzoates; Blotting, Western; Cell Cycle; Cell Proliferation; Cisplatin; Deferasirox; Drug Synergism; Humans; Iron Chelating Agents; Stomach Neoplasms; Triazoles; Tumor Cells, Cultured

2016